A PYMNTS Company

Astellas Pharma Acquires Iveric Bio For $5.9 Billion

By  |  May 1, 2023

Astellas Pharma Inc has reached an agreement to acquire Iveric Bio Inc for $5.9 billion in cash, valuing each share at $40.00.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Astellas has made a deal with Iveric Bio, a company that concentrates on finding and creating new treatments in ophthalmology. This partnership is expected to further Astellas’ main focus on “Blindness & Regeneration.”

    In February 2023, the company stated that the FDA had accepted a marketing application requesting approval for Avacincaptad Pegol (ACP) for the treatment of age-related macular degeneration (AMD) secondary to geographic atrophy (GA).

    Read more: Japan/US: Astellas to buy Audentes for $3B

    The agency has given ACP priority review, with a PDUFA date of August 19. If approved, the treatment could be available for commercialization by year-end.

    ACP, which is marketed as Zimura, is designed for targeting the C5 protein that has been linked with the development of scarring related with the disease.